Skip Navigation

Fellowship Leaders

ArellanoMartha L. Arellano, MD
Director

Martha L. Arellano, MD is Associate Professor of Hematology and Medical Oncology at Emory University School of Medicine and a member of the Winship Cancer Institute of Emory University in Atlanta, Georgia.  Dr. Arellano received her Medical Degree in 2000, completed Internal Medicine residency in 2003, and Hematology/Oncology fellowship in 2006 at Emory University School of Medicine. Dr. Arellano is actively involved in the training of fellows, medical students, and house staff, specifically focusing on diagnosis and management of hematological disorders.

Dr. Arellano is an active clinical investigator with a primary focus on developing novel therapies for adults with acute leukemias and myelodysplastic syndromes, and immune-based therapies for hematological malignancies. She has published in leading journals including Journal of Clinical Oncology, Biology of Blood and Marrow Transplantation and Leukemia and Lymphoma, among others.  She serves on multiple committees at the Winship Cancer Institute of Emory University including, the Data Safety Monitoring Committee (DSMC), Chemotherapy Quality and Safety Council, and the Pharmacy and Therapeutics Subcommittee. She has also served on the University’s Community and Diversity Committee to develop strategies for retention and development of students and trainees at Emory University. Dr. Arellano participates in the American Society of Hematology Grassroots Network and was nominated to the Advocacy Leadership Institute.    


Taofeek OwonikokoTaofeek K. Owonikoko, MD, PhD
Associate Director

Dr. Taofeek Owonikoko is Assistant Professor of Hematology and Medical Oncology At Emory School of Medicine. He obtained his primary Medical Degree from the Obafemi Awolowo University, Ile-Ife Nigeria in 1991. He received specialty training in Anatomic Pathology at the Lagos University Hospital, Lagos Nigeria and at the Heinrich Heine University, Dusseldorf, Germany. He also completed doctoral research work and obtained his PhD in Anatomic Pathology from the Heinrich Heine University, Germany from where he was recruited to the Johns Hopkins University, Baltimore in 2000 as a postdoctoral fellow in nuclear imaging. He subsequently completed a residency training in Internal Medicine at the Graduate Hospital of Drexel University in Philadelphia from 2002 to 2005. His clinical fellowship training in Hematology and Oncology took place at the University of Pittsburgh Medical Center from 2005-2008. Dr. Owonikoko has been designated a Distinguished Cancer Scholar by the Georgia Cancer Coalition since 2008 when he joined the staff of Emory University as an Assistant Professor in the Department of Hematology & Medical Oncology. Dr. Owonikoko has participated in many training workshops devoted to clinical and translational research. He was a participant in the world-famous VAIL training workshop jointly sponsored by AACR/ASCO. He also participated in the visiting physician program of the Investigational Drug Branch of the National Cancer Institute in Bethesda as well as in the FDA-sponsored Clinical Investigator Training workshop.

Ragini KudchadkarRagini Kudchadkar, MD
Associate Director

Dr. Kudchadkar is Assistant Professor at Emory University School of Medicine. Dr. Kudchakar completed medical school at Emory University in 2003 and went on to complete her internal medicine residency at Emory as well in 2006. She then pursued her hematology and medical oncology training at the University of Colorado where she began her interest in Cutaneous oncology. After completing fellowship, she was an Assistant member at H. Lee Moffitt Cancer Center in Tampa, Florida in the Department of Cutaneous Oncology. Dr. Kudchadkar’s research focuses on signal transduction inhibitors for the treatment metastatic melanoma with a secondary interest in advanced basal cell carcinomas. Her research is focused on the development of novel therapeutic approaches for metastatic melanoma via the discovery of novel drug targets and drug combinations. Her concentration at Emory is in clinical trial development and implementation to improve treatment options for melanoma.

Jean WilbournJean Wilbourn
Program Associate






Back to Top